Gestational Age (weeks), Mean ± SD |
31.41±0.30 |
31.36 ± 0.69 |
0.57* |
Gestational age group |
|
|
|
28 to < 32 weeks, n (%) |
49 |
50 |
0.90** |
32 to < 34 weeks, n (%) |
23 |
23 |
|
≥ 34 weeks, n (%) |
03 |
02 |
|
SGA n (%) |
32 |
35 |
0.74*** |
AGA n (%) |
43 |
40 |
|
LGA n (%) |
00 |
00 |
|
Birth weight, g, Mean ± SD |
1226 (±176) |
1261.5 (±244) |
0.30* |
Birth weight group |
|
|
|
ELBW (<1000 g) |
08 |
09 |
0.49** |
VLBW (1000–1499 g) |
59 |
62 |
|
LBW (1500–2499 g) |
08 |
04 |
|
Gender |
|
|
|
Male, n (%) |
39 |
41 |
0.87*** |
Female, n (%) |
36 |
34 |
|
APGAR Score, Median (IQR) |
|
|
|
1 min |
5(4-6) |
5(5-6) |
0.25# |
5 min |
7(7-8) |
8(7-8) |
0.56# |
Mode of delivery |
|
|
|
Vaginal, n (%) |
55(73.33%) |
52(69.33%) |
0.71*** |
Caesarean, n (%) |
20(26.66%) |
23(30.66%) |
|
Antenatal steroids |
|
|
|
Complete course, n (%) |
22 (29.33%) |
21 (28 %) |
0.98** |
Incomplete course, n (%) |
37 (49.33%) |
38(50.66%) |
|
Not received, n (%) |
16(21.33%) |
16(21.33%) |
|
Antenatal complications |
|
|
|
GDM, n (%) |
03 |
02 |
0.97** |
PIH |
29 |
32 |
|
ECLAMPSIA |
05 |
04 |
|
APH |
16 |
15 |
|
PPROM |
24 |
22 |
|
MAX PEEP before surfactant, Median (IQR) |
7 (6-7) |
7 (6-7) |
0.87# |
Age at surfactant therapy (hrs),
Mean ± SD
|
2.98 ± 0.70
|
2.8 ± 0.79
|
0.13*
|
SAS Score before surfactant, Median (IQR) |
5(5-6) |
5 (5-6) |
0.89# |